retatrutide sources for Weight Loss: TRIUMPH-1 Results, Cost, Insurance Demand for Unapproved Weight-Loss Drug

The phase 3 SURMOUNT programme assessed the safety and efficacy of tirzepatide as obesity treatment and the medication has now been approved (November 2023) for chronic weight management by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [46, 47]

This shift toward a higher serotonin-to-dopamine ratio can result in a subtle blunting of the reward response

skin-specific effects were not highlighted as a primary safety signal, though injection site reactions were noted as expected with subcutaneous administration

All findings are preclinical

Exercise also supports better sleep, improved mood and stress relief, all of which make it easier to stick with healthy routines